Doctors are saying about 'A-Fib.com'...

"A-Fib.com is agreat web site for patients, that is unequaled by anything else out there"

Dr. Douglas L. Packer, MD, FHRS, Mayo Clinic, Rochester, MN

" Think your site has helped a lot of patients"

Dr. Hugh G. Calkins, MD Johns Hopkins,Baltimore, MD

"Thank you for your efforts in educating patients on the topic of atrial fibrillation. I am an electrophysiologist and have a special passion for the treatment of atrial fibrillation. Please continue your important work - it is commendable and appreciated"

Dr. Ruan Louw, Gauteng Republic of South Africa

"Enjoyed your Afib website….a great resource for patients seeking solid, reliable information on Afib"

Matthew S. Forcina, MD, Cardiac Electrophysiology, Raleigh, NC

"Thank you for your website…for being there for us “Afibbers"

Dr. M. Van Zeebroeck, Irvine, CA

Patients are saying about 'A-Fib.com'...

"Jill and I put you and your work in our prayers every night. What you do to help people through this [A-Fib] process is really incredible"

Jill & Steve Douglas, E. Troy, WI

"I really appreciate all the information on your website as it allows me to be a better informed patient and to know what questions to ask my EP."

Faye Spencer, Boise, ID

"I am extremely grateful for your help to me. Thank you Dr Ryan. Because of you, I now have a wonderful change to my life"

Alan Davidson

"Steve, Your web page is fantastic. It has been helpful as I learn about A-Fib and work towards finding my cure. You do a great job making the web page user friendly and informative. I am very grateful and appreciative for your web site and your personal time and experience"

Chris Daniels

"An awesome mission. I am eager to cure my AFib and this information will make the success of that quest much easier and much more likely. Thank you again."

Jean Beer

Front-End Snidget Title

special image

2021 AF Symposium

Spotlight Session: Drug in Development from Acesion Pharma

At this year’s AF Symposium, there were 22 Spotlight Session talks 5 minutes long spread out over 3 days. Normally I don’t report on them in detail, since they usually aren’t currently available (and may never make it through development and regulatory hurdles into the marketplace). But here’d one that may be of interest to patients.
Dr. John Camm - A-Fib.com

Dr. John Camm

Dr. John Camm of St. George’s Hospital in Oxford, UK discussed a drug in development from Acesion Pharma, a Danish biotech company.

This new drug (AP30663) is highly atrial specific and works as an SK channel inhibitor [to suppress A-Fib]. SK channel inhibitors are ion channels present in the heart which regulate the cardiac rhythm.

Acesion’s new drug is designed for IV cardioversion of A-Fib to normal sinus rhythm.

Editor’s Comments:

Just the fact that Acesion is working on a new antiarrhythmic drug is news in itself. It’s been years since any new antiarrhythmic drugs have come on the market. And the antiarrhythmic drugs currently available to patients leave a lot to be desired.

Plus, the Acesion drug being developed is highly atrial specific which is an important advantage over most other antiarrhythmics.

If you find any errors on this page, email us. Y  Last updated: Monday, April 19, 2021

Return to 2021 AF Symposium Reports

Related Posts

author-icon

AUTHOR PROFILE

Steve Ryan, PhD

Former A-Fib patient, patient advocate, and founder of A-Fib.com. Read Steve’s story
tick-icon

Our Mission

We offer hope & guidance to empower patients to find their A-Fib cure or best outcome. A-Fib.com is the patient's unbiased information on current & emerging Atrial Fibrillation treatments.
 

What Do We Stand For?

Learn more

We Need You

Help A-Fib.com be an independent source for unbiased patient information.

Support via Amazon
Shop using our link